Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.44)
# 316
Out of 5,049 analysts
229
Total ratings
44.59%
Success rate
31.41%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $86.06 | +77.78% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $57.00 | +10.53% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $30.44 | +162.81% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $32.46 | +223.48% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $67.72 | +74.25% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $82.71 | -10.53% | 2 | Aug 27, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $23 → $32 | $28.38 | +12.76% | 8 | Aug 6, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $5.45 | +101.83% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $9.79 | +196.22% | 3 | Jul 10, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $4.41 | +263.22% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 | $8.37 | +19.47% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $6.06 | +395.05% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $16.20 | +400.00% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.27 | +63.93% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $63.85 | +92.64% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.97 | +2,167.00% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.78 | +293.26% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.63 | +70.88% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $23.85 | +180.92% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $8.99 | +133.59% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $6.08 | +179.61% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.85 | +180.70% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.17 | +406.91% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.56 | +294.74% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.42 | +885.92% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.46 | +790.41% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.35 | +1,455.56% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.80 | +233.33% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.21 | +1,552.89% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.87 | +494.32% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.27 | +70,766.14% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $5.96 | +6,611.41% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.53 | +5,455.56% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.92 | +2,501.16% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.67 | +6,641.57% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.43 | +669.23% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.90 | +6,551.15% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.22 | +7,277.05% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.19 | +211,629.12% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.41 | +39,308.87% | 1 | Jan 9, 2020 |
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $86.06
Upside: +77.78%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $57.00
Upside: +10.53%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $30.44
Upside: +162.81%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $32.46
Upside: +223.48%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $67.72
Upside: +74.25%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $82.71
Upside: -10.53%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23 → $32
Current: $28.38
Upside: +12.76%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.45
Upside: +101.83%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $9.79
Upside: +196.22%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $4.41
Upside: +263.22%
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $8.37
Upside: +19.47%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.06
Upside: +395.05%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $16.20
Upside: +400.00%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.27
Upside: +63.93%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $63.85
Upside: +92.64%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.97
Upside: +2,167.00%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.78
Upside: +293.26%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.63
Upside: +70.88%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $23.85
Upside: +180.92%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $8.99
Upside: +133.59%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $6.08
Upside: +179.61%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.85
Upside: +180.70%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.17
Upside: +406.91%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.56
Upside: +294.74%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.42
Upside: +885.92%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.46
Upside: +790.41%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.35
Upside: +1,455.56%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.80
Upside: +233.33%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.21
Upside: +1,552.89%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.87
Upside: +494.32%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.27
Upside: +70,766.14%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $5.96
Upside: +6,611.41%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.53
Upside: +5,455.56%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.92
Upside: +2,501.16%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $2.67
Upside: +6,641.57%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.43
Upside: +669.23%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $0.90
Upside: +6,551.15%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.22
Upside: +7,277.05%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.19
Upside: +211,629.12%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.41
Upside: +39,308.87%